|
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
|
Feb 2012
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia
|
Feb 2013
|
Leukemia
|
aplastic anemia
|
|
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
|
Jun 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium
|
Jan 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
|
May 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
|
Jul 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
